How PlexusDx Supports a More Personalized Approach PlexusDx integrates biomarker context and genetic predisposition mapping into the GLP-1 selection process for uninsured patients
Venter C, Meyer RW, Nwaru BI, Roduit C, Untersmayr E, Adel-Patient K, Agache I, Agostoni C, Akdis CA, Bischoff SC, du Toit G, Feeney M, Frei R, Garn H, Greenhawt M, Hoffmann-Sommergruber K, Lunjani N, Maslin K, Mills C, Muraro A, Pali-Schll I, Poulson LK, Reese I, Renz H, Roberts GC, Smith P, Smolinska S, Sokolowska M, Stanton C, Vlieg-Boerstra B, OMahony L
This usually relates to rapid weight loss and reduced nutrient intake rather than direct medication effects
Adding GIP activity isn't just "more of the same." GIP appears to recruit different brain circuits
It isnt surprising when you consider that 12% of US adults have already been using GLP-1 pharmaceuticals